- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06217666
Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)
January 19, 2024 updated by: Haoming (Carl) Qiu
A Phase 1, Prospective, Standard Dose Escalation Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)
The purpose of this study is to determine whether a new treatment combining radiation therapy with PCX12 is safe and tolerable.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
Single center, open label, escalating dosage of PCX12 with standard of care practice for subjects who are diagnosed with adenocarcinoma of the head of the pancreas.
Subjects with undergo standard of care radiation therapy and then start on PCX12 therapy starting at 200 ng/kg of PCX12 escalating to a potential maximum dosage of 800 ng/kg of PCX12 with adjacent tolerability and safety guidelines.
Study Type
Interventional
Enrollment (Estimated)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Haoming Qiu
- Phone Number: 585-275-5863
- Email: WCICTOResearch@URMC.Rochester.edu
Study Locations
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester
-
Contact:
- Haoming Qiu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patient with pathologically proven diagnosis of adenocarcinoma of the pancreas
- Initially staged as locally advanced by National Comprehensive Cancer Network (NCCN) criteria of solid tumor contact with aorta, superior mesenteric artery (SMA) or celiac axis >180 degrees and/or unreconstructable superior mesenteric vein/portal vein (SMV/PV) due to portal involvement or occlusion, tumor contact with most proximal draining jejunal branch into SMV
- Have completed first line chemotherapy without progression or non-regional metastases
- Tumor is radiographically evident on CT scan after chemotherapy
- Tumor is anatomically amenable to SBRT, e.g. does not directly invade the stomach or bowel
- Tumor is amenable to intra-tumor injection under endoscopic ultrasound guidance
- ECOG performance status 0-2
- Patients with childbearing potential must demonstrate a negative urine or serum pregnancy test
- Male or female subjects, aged at least 18 years; Female subjects of childbearing potential may participate if adequate contraception is used during, and for at least the three months after study completion; Male subjects with partners of childbearing potential may participate in the study if they had a vasectomy at least 6 months prior to randomization or if adequate contraception is used during, and for at least the three months after study completion; Adequate contraception is defined as resulting in a failure rate of less than 1% per year
- Patient must be able to understand and willingly sign study specific informed consent prior to study entry
- Anticipated life expectancy ≥ 12 weeks
- Patients aged at least 18 years of age
Exclusion Criteria:
- Progression of disease or metastatic disease after first line systemic therapy
- Prior radiation treatment or surgical resection of any pancreatic malignancy
- Inability to tolerate SBRT, Endoscopic ultrasound or IL-12 Injection procedure
- Lack of radiographically evident disease after first line chemotherapy
- Severe, active comorbidity that shortens the patient's life expectancy to less than 12 weeks
- History of past malignancy
- Patient who is pregnant and/or breastfeeding
- Inability to comply with other required protocol procedures including required biopsies
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PCX-12
PCX-12 is an experimental immunotherapy drug that is injected into the pancreatic cancer one time in attempt to stimulate the patient's immune system to fight the cancer.
|
treatment combining radiation therapy with PCX12
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])
Time Frame: 3 years
|
The Primary objective of the safety lead in component is to report acute, attributable, gastrointestinal toxicity
|
3 years
|
Maximum tolerable dose [Safety and Tolerability]
Time Frame: 3 years
|
Maximum tolerable dose is defined by less than or equal to 30% dose limiting toxicity (DLT) event rate within a given dose
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of radiographic response
Time Frame: 2 months
|
This study will assess radiographic response following SBRT and PCX12 utilizing RECIST 1.1 criteria
|
2 months
|
Change in biomarkers of innate and adaptive immunity
Time Frame: baseline and 4 weeks
|
A combination of flow/mass cytometry will be employed to assess intratumoral immune cells before and after treatment.
Specifically, cells of the adaptive immune system, namely B and T cells (both CD4+ and CD8+), along with innate cells including monocytes, macrophages, neutrophils, and natural killer cells will be investigated and percent of total CD45+ cells along with absolute cell number will be tabulated.
Additionally, markers of activation (IFNg, TNF, etc.) along with suppression (PD1, PD-L1, LAG3, etc.) will be included in the panel of analysis.
|
baseline and 4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Haoming Qiu, University of Rochester
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
October 31, 2024
Primary Completion (Estimated)
January 1, 2027
Study Completion (Estimated)
January 1, 2028
Study Registration Dates
First Submitted
January 9, 2024
First Submitted That Met QC Criteria
January 19, 2024
First Posted (Actual)
January 22, 2024
Study Record Updates
Last Update Posted (Actual)
January 22, 2024
Last Update Submitted That Met QC Criteria
January 19, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UGIP20052
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Adenocarcinoma
-
Fudan UniversityUnknownStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Roswell Park Cancer InstituteNot yet recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditionsUnited States
-
Xian-Jun YuCompletedStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Xian-Jun YuCompletedStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Scandion Oncology A/SAlcedis GmbHRecruitingMetastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Inoperable Disease | Localized Pancreatic AdenocarcinomaDenmark, Germany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingPancreas Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic AdenocarcinomaUnited States
-
Lawson Health Research InstituteLondon Health Sciences FoundationNot yet recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenocarcinoma
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
Jean-Luc Van LaethemCelgene CorporationCompletedPancreatic Adenocarcinoma Resectable | Pancreatic Adenocarcinoma Metastatic | Pancreatic Adenocarcinoma Locally AdvancedBelgium
Clinical Trials on PCX-12
-
Jenny Craig, Inc.CompletedTime Restricted FeedingUnited States
-
Stanford UniversityActive, not recruiting
-
University of FloridaNational Institute on Aging (NIA)Recruiting
-
Beth Israel Deaconess Medical CenterNational Center for Complementary and Integrative Health (NCCIH)Completed
-
Afyonkarahisar Health Sciences UniversityActive, not recruiting
-
VA Office of Research and DevelopmentBaltimore VA Medical Center; South Texas Veterans Health Care SystemNot yet recruitingObesity | Post-COVID ConditionsUnited States
-
VA Office of Research and DevelopmentNot yet recruitingDiabetic Foot UlcerUnited States
-
MetroHealth Medical CenterVA Office of Research and Development; Case Western Reserve University; FDA Office...Active, not recruitingSpinal Cord Injury | TetraplegiaUnited States
-
Cascadian Therapeutics Inc.CompletedMetastatic Cancer | Advanced CancerUnited States
-
Fundación del Caribe para la Investigación BiomédicaCompleted